We also investigated whether the HA in the LSC niche could have a role in regulating LSC specification. For such, we stained for LSCs (K15
+ cells) and differentiated corneal epithelial cells (K12
+ cells) in
HAS1−/−;HAS3−/− and
HAS2ΔCorEpi mice. Interestingly,
HAS2ΔCorEpi mice induced at P7 presented a loss of LSCs in the corneal limbus, indicating that the loss of HAS2 leads to LSCD. Moreover,
HAS2ΔCorEpi mice presented primarily goblet cells in the peripheral cornea and sparse goblet cells in the central cornea after alkali burn. A hallmark of LSCD is conjunctivalization of the cornea, which is the invasion of conjunctival surface cells (goblet cells) onto the corneal surface.
3,26 Therefore, the presence of goblet cells in the corneal epithelium after injury further supports the notion that the loss of HAS2 leads to LSCD. Taken together, our results indicate that
HAS2ΔCorEpi mice could be a useful model for studying LSCD. Curiously, after injury, both
HAS1−/−;HAS3−/− and
HAS2ΔCorEpi mice presented an increase in HA expression, which, after alkali burn, is present throughout the cornea. Therefore,
HAS1−/−;HAS3−/− mice up-regulate HAS2 as a compensatory mechanism after injury, whereas
HAS2ΔCorEpi mice up-regulate HAS1 and/or HAS3 expression after injury. The change in HA distribution in the cornea from being located solely in the corneal limbus to being expressed throughout the corneal epithelium in turn alters the distribution of LSCs. Interestingly, the change in HA distribution leads to the presence of LSCs throughout the corneal epithelium and the absence of differentiated corneal epithelial cells. These data indicate that the HA microenvironment maintains the LSC phenotype. Thus, as LSCs migrate out of the LSC niche, the lack of an HA environment could trigger their differentiation into corneal epithelial cells. Curiously,
HAS2ΔCorEpi mice induced at P7 lacked both HA and LSCs (K15
+ cells) in the corneal limbus and instead presented corneal epithelial cells (K12
+ cells); however, after injury these mice were able to switch from solely K12
+ cells to K15
+ cells. How mice lacking LSCs were able to generate de novo LSCs remains to be determined. Previous studies have demonstrated that corneal epithelial cells have high regenerative and migratory potential.
83,84 Moreover, Majo et al.
83 were also able to show that corneal epithelial cells could assume either a conjunctival or epithelial cell phenotype depending on the site of transplantation; however, these findings have been met with some controversy. Our data show that the K12
+ to K15
+ cell switch coincides with the up-regulation of HA, further indicating that HA could regulate LSC and corneal epithelial specification. Therefore, the up-regulation of HA synthesis within the corneal limbus could provide a viable therapeutic approach for treating LSCD. Whether the ultrastructure and composition of the HA matrix and length of the HA chains present throughout the cornea in
HAS1−/−;HAS3−/− and
HAS2ΔCorEpi mice after injury are similar to the HA found in the healthy LSC niche remains to be elucidated.
TSG-6−/− mice showed altered HA expression in the LSC niche and increased inflammation after alkali burn. In the
TSG-6−/− mice the absence of TSG-6 could potentially lead to a less compact/stable HA matrix, which could affect the migration of LSCs and inflammatory cells. Therefore, our data indicate that potentially a specialized HC-HA/TSG-6 matrix could be present in the corneal LSC niche; however, further research is necessary to fully characterize the composition of this matrix. Amniotic membrane based therapies for treating LSCD have been studied for many years.
30,31,56,85,86 The Tseng group have determined that a HC-HA/PTX3 complex is the pharmacologically active component of the amniotic membrane commonly used for treating ocular surface disorders, including LSCD.
30 Substantial studies have demonstrated that HC-HA/PTX3 complexes attain powerful anti-inflammatory properties, and this complex was hypothesized to improve the outcome of LSCD patients by suppressing the inflammatory response. Our data indicate that the therapeutic properties of the amniotic membrane could go beyond simply suppressing inflammation. The HC-HA/TSG-6 complex released by the amniotic membrane could provide support to LSCs forming a transient LSC niche for any residual LSCs.